Brokerages expect Adaptimmune Therapeutics PLC (NASDAQ:ADAP) to announce earnings per share (EPS) of ($0.27) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Adaptimmune Therapeutics PLC’s earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.24). Adaptimmune Therapeutics PLC reported earnings per share of ($0.24) in the same quarter last year, which suggests a negative year over year growth rate of 12.5%. The business is expected to announce its next earnings report on Thursday, November 9th.

On average, analysts expect that Adaptimmune Therapeutics PLC will report full-year earnings of ($0.95) per share for the current fiscal year, with EPS estimates ranging from ($1.12) to ($0.54). For the next fiscal year, analysts expect that the firm will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.28) to ($0.24). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Adaptimmune Therapeutics PLC.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) EPS for the quarter, hitting the consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. The business had revenue of $3.52 million during the quarter, compared to analyst estimates of $5.43 million.

A number of analysts have recently commented on the company. Leerink Swann restated an “outperform” rating and set a $15.00 price objective on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. BidaskClub upgraded Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine upgraded Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Zacks Investment Research downgraded Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Finally, Cowen and Company restated a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $12.08.

Institutional investors have recently made changes to their positions in the stock. AXA purchased a new stake in Adaptimmune Therapeutics PLC during the 1st quarter worth $4,959,000. Alps Advisors Inc. boosted its position in Adaptimmune Therapeutics PLC by 4.9% during the 2nd quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock worth $287,000 after purchasing an additional 2,996 shares during the period. Point72 Asset Management L.P. purchased a new stake in Adaptimmune Therapeutics PLC during the 1st quarter worth $2,883,000. Raymond James Financial Services Advisors Inc. purchased a new stake in Adaptimmune Therapeutics PLC during the 1st quarter worth $120,000. Finally, Vident Investment Advisory LLC boosted its position in Adaptimmune Therapeutics PLC by 20.0% during the 1st quarter. Vident Investment Advisory LLC now owns 232,641 shares of the biotechnology company’s stock worth $1,282,000 after purchasing an additional 38,772 shares during the period. 68.01% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/27/zacks-analysts-anticipate-adaptimmune-therapeutics-plc-adap-will-announce-earnings-of-0-27-per-share.html.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Get a free copy of the Zacks research report on Adaptimmune Therapeutics PLC (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.